We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Risk Loci Identified for Polycystic Ovary Syndrome

By LabMedica International staff writers
Posted on 09 Jan 2019
Print article
Image: A diagram showing normal and polycystic ovary syndrome, in the latter the ovaries may develop numerous small collections of fluid (follicles) and fail to regularly release eggs (Photo courtesy of Mayo Clinic).
Image: A diagram showing normal and polycystic ovary syndrome, in the latter the ovaries may develop numerous small collections of fluid (follicles) and fail to regularly release eggs (Photo courtesy of Mayo Clinic).
Polycystic ovary syndrome is a disorder characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology. Affected women frequently have metabolic disturbances including insulin resistance and dysregulation of glucose homeostasis.

Polycystic ovary syndrome (PCOS) is diagnosed with two different sets of diagnostic criteria, resulting in a phenotypic spectrum of PCOS cases. The genetic similarities between cases diagnosed based on the two criteria have been largely unknown.

An international team of scientists working with the University of Utah (Salt Lake City, UT) performed a genome-wide association study meta-analysis involving 10,074 individuals with PCOS and 103,164 without, leading to three previously undetected loci and 11 loci linked to the endocrine disorder in the past. Of those, 13 loci were associated with self-reported PCOS and cases diagnosed using National Institutes of Health or Rotterdam criteria.

PCOS diagnoses are based on excess androgen hormone levels and ovulatory dysfunction, the team explained, which represents roughly 7% of reproductive age women around the world. On the other hand, more general criteria from Rotterdam defined PCOS as polycystic ovarian morphology in combination with either hyperandrogenism or ovulatory dysfunction, representing an estimated 15% to 20% of women globally.

The team reported new associations at loci in or around the PLGRKT, ZBTB16, and MAPRE1 genes, which are believed to contribute to metabolic and reproductive pathways. The meta-analysis also led to 11 known risk loci, which were overrepresented for variants in and around genes from neuroendocrine and metabolic pathways. The set of known risk loci included half a dozen sites previously implicated in PCOS in women of Han Chinese ancestry, and a variant near the GATA4/NEIL2 genes that showed strong ties to the PCOS diagnosed using NIH criteria but weaker associations to the self-reported PCOS cases.

The authors concluded that the genetic underpinnings of PCOS implicate neuroendocrine, metabolic, and reproductive pathways in the pathogenesis of disease. Although specific phenotype stratified analyses are needed, genetic findings were consistent across the diagnostic criteria for all but one susceptibility locus, suggesting a common genetic architecture underlying the different phenotypes. The study was published on December 19, 2018, in the journal PLOS Genetics.

Related Links:
University of Utah

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more